Navigation Links
Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
Date:10/18/2007

SAN MARINO, Calif., Oct. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA. On October 22, 2007 at 8:00 a.m., Dr. Hall will present the scientific principles, the clinical validation, and global development status of the company's innovative pathotropic (disease-seeking) -- targeting technology embodied in its lead product, Rexin-G, the first pathotropically targeted genetic medicine developed for the treatment of advanced-stage and metastatic cancer.

(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

The Global Pharma R&D Summit 2007 (http://www.globalpharmasummit.com), which will be held at the Boston Marriott Hotel, Newton MA 02466 USA, on October 22-23, 2007, showcases cutting-edge biotechnology and pharmaceutical companies that are developing superior technologies and products in healthcare and healthcare related areas, and offers a forum to meet with suppliers, service providers, opinion leaders, and representatives from other leading pharmaceutical and biotechnology companies worldwide. The Keynote Address provides an opportunity for Epeius to update the industry in regard to its recent clinical developments and global partnering initiatives to expedite the international development of Rexin-G, which is currently in clinical trials in Europe, Japan, and ASEAN member countries, as well as the United States.

The focus on Epeius Biotechnologies during National Breast Cancer Awareness Month, is apropos-for the company has just opened an Advanced Phase I/II trial for chemo-resistant breast cancer in San Marino and Santa Monica California. Rexin-G, has received Orphan Drug Status from the FDA based on unp
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
2. Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System
3. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
4. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
5. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
7. Performance of fluorescent dyes with LEADseeker Multimodality Imaging System
8. Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System
9. Use of BRET2 luminescence cell-based assays with LEADseeker Multimodality Imaging System
10. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
11. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)...  Edico Genome today announced that collaborative data ... Stanford Universities showed the DRAGEN™ Bio-IT Processor sped ... depth of coverage by tenfold, generating results in ... standard software. "Processing large amounts of ... research and clinical labs, in terms of the ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , 27 avril 2015 /PRNewswire/ ... médicamenteuse spécialisée dans le développement d,une ... soigner les infections bactériennes polypharmacorésistantes potentiellement ... de données prouvant les promesses de ... dans la lutte contre la résistance ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... is Well-Positioned to Expand Business Development Efforts, ... Inc., a company,focused on the development of molecular ... market, announced today that Joe Ross has,joined the ... President of,Strategic Initiatives., In this new role, ...
... WARSAW, Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ... subsidiaries have,agreed to acquire the Abbott Spine business from ... expects to fund the purchase price,from cash on hand ... is expected to close in the fourth quarter of ...
... Ohio State University,Medical Center has invited experts from ... the laboratory to clinical health,care practice during the ... Health care leaders, government policy makers, health care ... patient,advocacy groups will be among the more than ...
Cached Biology Technology:Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4OSU to Host National Personalized Health Care Conference 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) ... Recognition Market in Automotive Sector 2014-2018" report to ... Gesture Recognition market in Automotive Sector to grow at ... Gesture recognition is the ability of a device ... individual. Gesture recognition technology can be 2D-based or 3D-based. ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... Inc. (TSX-V: IOT), a pioneer in the field of biofilm ... Ltd of Israel to market and distribute its bioFILM PA ... very excited to enter into this agreement with LevPharm, who ... on improving patient care while reducing the cost burden to ...
... blue-green algae out-compete other organisms through a form of ... in freshwater bodies -- has been described by a ... In general, the increasing occurrence of toxic cyanobacterial (blue-green ... growing international concern due to their detrimental impact on ...
... 2010 A new report, Agriculture,s Role in Greenhouse ... of Agronomy, Crop Science Society of America, and Soil ... gas (GHG) emissions and sequestration in America,s major agroecosystems. ... (CO2), nitrous oxide (N2O) and methane (CH4) emissions and ...
Cached Biology News:How algae 'enslavement' threatens freshwater bodies described by Hebrew University researcher 2US greenhouse gas emissions and capture, regionally 2
... experimental process of determining the nucleotide sequence ... Sequencing is based on Sangers enzymatic method ... cycle sequencing reactions. The resulting fluorescent products ... instrument controlled by a computer and the ...
... Anti-phospho-Lck (pTyr 192 ) The antibody is preadsorbed ... affinity isolated antibody buffered aqueous glycerol solution ... saline (without Mg 2+ and Ca 2+ ... 1.0 mg/mL BSA (IgG, protease free) and 0.05% ...
... calibration, and validation (MCV) plate ... used for hands-free startup, shutdown, ... the Bio-Plex suspension array system. ... use with Bio-Plex Manager software ...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
Biology Products: